DGAP-Adhoc: Pulsion Medical Systems SE: Pulsion and MAQUET

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jul 3, 2014 at 2:45 PM

DGAP-Adhoc: Pulsion Medical Systems SE: Pulsion and MAQUET will enter into a domination and profit and loss transfer agreement

Pulsion Medical Systems SE / Key word(s): Miscellaneous 03.07.2014 20:38 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Release according to Â§15 (German) Securities Trade Act (Wertpapierhandelsgesetz, WpHG) Pulsion and MAQUET will enter into a domination and profit and loss transfer agreement The administrative board of Pulsion Medical Systems SE today approved the conclusion of a domination and profit and loss transfer agreement pursuant to sec. 291 et seqq. of the German Stock Corporation Act (Aktiengesetz, AktG) between Pulsion Medical Systems SE as the controlled entity and MAQUET Medical Systems AG (an indirect subsidiary of Getinge AB, Sweden) as the controlling entity. MAQUET Medical Systems AG currently owns 78.26% of the shares of Pulsion Medical Systems SE (including the own shares held by Pulsion Medical Systems SE which amount to 0.06% of the registered share capital). The domination and profit and loss transfer agreement requires the approval by the extraordinary general meeting of Pulsion Medical Systems SE, which is scheduled to take place in Munich on 14 August 2014, and the approval by the general meeting of MAQUET Medical Systems AG. In the agreement, MAQUET Medical Systems AG offers to acquire the shares of the minority shareholders of Pulsion Medical Systems SE for a cash compensation pursuant to sec. 305 AktG in the amount of 17.03 EUR per share. The cash compensation corresponds to the volume-weighted average stock market price of Pulsion Medical Systems SE shares as determined by the German Federal Financial Supervisory Authority (BaFin) for the relevant three-month period up to and including 17 February 2014. On this day, MAQUET Medical Systems AG announced that the minimum acceptance threshold had been met and its intention to enter into a domination and profit and loss transfer agreement with Pulsion Medical Systems SE. The applicable reference share price for the cash compensation is higher than the company value per Pulsion Medical Systems SE share as determined in an independent valuation of Pulsion Medical Systems SE carried out by KPMG AG WirtschaftsprÃ¼fungsgesellschaft in accordance with IDW Standard S 1. It is also slightly higher than the price offered by MAQUET Medical Systems AG within the context of its public takeover offer. The domination and profit and loss transfer agreement also provides for an annual recurring compensation payment pursuant to sec. 304 AktG in the gross amount of 1.02 EUR (0.86 EUR net based on the current taxation) per share. The expert report by KPMG AG also includes a recent outlook for the current fiscal year 2014 ending on 31 December 2014. The current outlook for the ongoing fiscal year as reported in the expert report is within the scope of the guidance update for revenues and adjusted EBIT margin released in the quarterly report as of 31 March 2014. The domination and profit and loss transfer agreement as well as the joint report by the administrative board of Pulsion Medical Systems SE resp. the management board of MAQUET Medical Systems AG on the agreement together with the expert opinion by KPMG AG and the audit report of an independent court appointed auditor WEDDING & Cie. GmbH WirtschaftsprÃ¼fungsgesellschaft will be published together with the convocation for the extraordinary general meeting of Pulsion Medical Systems SE on the internet at www.pulsion.de in the next few days. Contact: Investor Relations PULSION Medical Systems SE Ralph SchÃ¤fer Director Legal Affairs Tel.: +49 (0)89 / 459914 211 Fax: +49 (0)89 / 459914 481 E-mail: schaefer@pulsion.com 03.07.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Pulsion Medical Systems SE Hans- Riedl- StraÃe 21 85622 Feldkirchen Germany Phone: +49 (0)89 4599 14-0 Fax: +49 (0)89 4599 14-18 E-mail: info@pulsion.com Internet: www.pulsion.com ISIN: DE0005487904 WKN: 548790 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...